Brief: Veracyte Says New Data Validate Clinical Utility Of Co’S Decipher Prostate Genomic Classifier To Help Guide Therapy In Men With Intermediate-Risk Prostate Cancer
15/02/2022 24:36
Feb 14 (Reuters) - Veracyte Inc VCYT.O :
* NEW DATA VALIDATE CLINICAL UTILITY OF VERACYTE’S DECIPHER
PROSTATE GENOMIC CLASSIFIER TO HELP GUIDE THERAPY IN MEN WITH
INTERMEDIATE-RISK PROSTATE CANCER
Source text for Eikon: ID:nBw7T1zMNa
Further company coverage: VCYT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina